Overview

Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies

Status:
Enrolling by invitation

Trial end date:
2021-12-16

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, extension study to evaluate the long-term safety of tislelizumab or pamiparib given either as monotherapy or in combination with each other or with other agents in participants with advanced malignancies who participated in a prior BeiGene sponsored clinical study (parent study).

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Capecitabine
Pemetrexed
Temozolomide